Considering the multifunctional activity of pan-PDE inhibitors in inflammation and fibrosis mitigation, it seems that designing new compounds targeting lung diseases not only in the group of 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione derivatives but also within other chemical groups may bring many therapeutic benefits in the future. Here, ALDH7A1 is linked to lung disorder.